Clinical research coverage analysis and billing are two of the most perplexing problems facing institutions, investigators, sponsors, and government agencies. A range of problems has resulted from the difficulties in determining which services are appropriate for reimbursement and documenting claims for those services, including costly governmental enforcement actions and millions of dollars being unbilled and uncollected.
This presentation will focus on the development and implementation of appropriate coverage analysis decision making and billing practices.
Presenters
Richard Takamoto, RN, is a principal of Kahu Health, LLC, a health care consulting, regulatory compliance, and Web development firm and collaborative effort of members from Verve Health, LLC and Tech Artisans, LLC.
Maria E. Gonzalez Knavel is a partner with Foley’s Health Care Industry Team and White Collar Defense & Corporate Compliance Practice.
Moderator
LaDale K. George is a partner with Foley’s Health Care Industry Team and is the leader of the Translational Research Focus Group.
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.